<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31367259</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1838-7640</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>16</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Theranostics</Title><ISOAbbreviation>Theranostics</ISOAbbreviation></Journal><ArticleTitle>Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.</ArticleTitle><Pagination><StartPage>4811</StartPage><EndPage>4826</EndPage><MedlinePgn>4811-4826</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.35919</ELocationID><Abstract><AbstractText>The viral E proteins of dengue virus (DENV) and Zika virus (ZIKV) are the major viral proteins involved in receptor binding and fusion, and for the induction of protective antibodies against viral infections. DIII of the E proteins is an independent domain and stretches out on the virion surface that can elicit type-specific neutralizing antibodies. For recombinant DIII vaccine development, prime-boost immunizations can provide an advantage of eliciting more type-specific neutralizing antibodies by recalling DIII antigens after DIII booster to improve protection. <b>Methods</b>: The DIII of the E genes of DENV and ZIKV were fused with bacterial <i>fliC</i> gene for the expression of flagellin-DIII (FliC-DIII) fusion proteins. Prime-boost immunization strategies by the second-dose booster of four DENV serotype or ZIKV FliC-DIII fusion proteins were used to investigate the induction of neutralizing antibodies and protection against viral infections. Cross-reactive non-neutralizing antibodies in each group of antisera were also examined using <i>in vitro</i> antibody-dependent enhancement (ADE) assay. A series of glycan-masking E antigens were finally constructed for prime-boost immunizations to abolish the elicitation of cross-reactive non-neutralizing antibodies for ADE activity. <b>Results</b>: We showed that inclusion of a bivalent live-attenuated vaccine with a FliC-DIII booster is superior in eliciting neutralization titers and protection <i>in vivo</i> against all four-serotype DENVs. We also demonstrated that recombinant adenovirus vectors encoding four-serotype DENV prMEs with a FliC-DIII prime-boost scheme is capable of eliciting good antibody responses. In contract, recombinant adenovirus vector of ZIKV prME gene priming, followed by ZIKV FliC-DIII booster did not improve vaccine efficacy. The glycan-masking mutation on the ZIKV E protein ij loop (E-248NHT), but not on DENV2 E protein ij loop (E-242NHT), resulted in abolishing the elicitation of cross-reactive antibodies for DENV and ZIKV infection enhancements. <b>Conclusions</b>: Our findings can provide useful information for designing novel immunogens and vaccination strategies in an attempt to develop a safe and efficacious DENV or ZIKV vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hsiao-Han</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu 30013, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shao-Ping</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu 30013, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Meng-Ju</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu 30013, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Guan-Cheng</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu 30013, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Han-Chung</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu 30013, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Science, National Tsing Hua University, Hsinchu 30013, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Theranostics</MedlineTA><NlmUniqueID>101552395</NlmUniqueID><ISSNLinking>1838-7640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12777-81-0</RegistryNumber><NameOfSubstance UI="D005408">Flagellin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005408" MajorTopicYN="N">Flagellin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011134" MajorTopicYN="N">Polysaccharides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012486" MajorTopicYN="N">Salmonella typhimurium</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071244" MajorTopicYN="N">Zika Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cross-reactive antibodies</Keyword><Keyword MajorTopicYN="N">dengue and Zika viruses</Keyword><Keyword MajorTopicYN="N">flagellin-domain III fusion</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">prime-boost vaccines</Keyword></KeywordList><CoiStatement>Competing Interests: H-HL, S-PY, M-JT, G-CL, S-CW are inventors on patents that cover prime-boost immunization and glycan masking E antigens for dengue and Zika vaccine development.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31367259</ArticleId><ArticleId IdType="pmc">PMC6643441</ArticleId><ArticleId IdType="doi">10.7150/thno.35919</ArticleId><ArticleId IdType="pii">thnov09p4811</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv. Virus Res. 2003;59:23&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">14696326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL. et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, Bahia, Brazil. Emerg Infect Dis. 2015;21(10):1885&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593454</ArticleId><ArticleId IdType="pubmed">26401719</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuler-Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A. et al. Brazilian Medical Genetics Society-Zika Embryopathy Task Force. Possible Association Between Zika Virus Infection and Microcephaly - Brazil, 2015. MMWR Morb. Mortal. Wkly. Rep. 2016;65(3):59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">26820244</ArticleId></ArticleIdList></Reference><Reference><Citation>Suy A, Sulleiro E, Rodo C, Vazquez E, Bocanegra C, Molina I. et al. Prolonged Zika Virus Viremia during Pregnancy. N. Engl. J. Med. 2016;375(26):2611&#x2013;2613.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959695</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatnagar J, Rabeneck DB, Martines RB, Reagan-Steiner S, Ermias Y, Estetter LB. et al. Zika Virus RNA Replication and Persistence in Brain and Placental Tissue. Emerg Infect Dis. 2017;23(3):405&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382738</ArticleId><ArticleId IdType="pubmed">27959260</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J. et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444521</ArticleId><ArticleId IdType="pubmed">26948433</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO Director-General summarizes the outcome of the Emergency Committee regarding clusters of microcephaly and Guillain-Barr&#xe9; syndrome (2016)</Citation></Reference><Reference><Citation>Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature. 1995;375(6529):291&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">7753193</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427(6972):313&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14737159</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons M, Murphy GS, Hayes CG. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg. 2001;65(2):159&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">11508393</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C. et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine. 2006;24(16):3165&#x2013;3171.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490289</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Yu M, Jiang T, Deng Y, Qin C, Qin E. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 2007;26(6):361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">17570760</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH. et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009;11(2):288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY. et al. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol. 2013;158(7):1523&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">23456422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Pan CH, Chen MY, Hsieh CH, Tsai JP, Liu HH. et al. Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice. Sci. Rep. 2016;6:30648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4965760</ArticleId><ArticleId IdType="pubmed">27470096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil L, Lazo L, Valdes I, Suzarte E, Yen P, Ramirez R. et al. The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection. Clin Transl Immunology. 2017;6(6):e148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518957</ArticleId><ArticleId IdType="pubmed">28748091</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Dent M, Lai H, Sun H, Chen Q. Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine. 2017;35(33):4287&#x2013;4294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546088</ArticleId><ArticleId IdType="pubmed">28669618</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Lai H, Sun H, Chen Q. Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Sci. Rep. 2017;7(1):7679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5550446</ArticleId><ArticleId IdType="pubmed">28794424</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P, Zhang W, Li D, Zhang C, Liu Q, Zhang X. et al. Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection. Antiviral Res. 2018;154:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">29665376</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes I, Gil L, Romero Y, Castro J, Puente P, Lazo L. et al. The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin. Vaccine Immunol. 2011;18(3):455&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067388</ArticleId><ArticleId IdType="pubmed">21209159</ArticleId></ArticleIdList></Reference><Reference><Citation>Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(7614):48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27338953</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead S. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis. 1979;140:527&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">117061</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ. 2005;83(4):308&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626214</ArticleId><ArticleId IdType="pubmed">15868023</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S. et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113(28):7852&#x2013;7857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948328</ArticleId><ArticleId IdType="pubmed">27354515</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007;104(22):9422&#x2013;9427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868655</ArticleId><ArticleId IdType="pubmed">17517625</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E. et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010;6(2):e1000790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820409</ArticleId><ArticleId IdType="pubmed">20168989</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat. Immunol. 2016;17(9):1102&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4994874</ArticleId><ArticleId IdType="pubmed">27339099</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SC. Immunogenic cross-talk between dengue and Zika viruses. Nat. Immunol. 2016;17(9):1010&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">27540984</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul LM, Carlin ER, Jenkins MM, Tan AL, Barcellona CM, Nicholson CO. et al. Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunology. 2016;5(12):e117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5192063</ArticleId><ArticleId IdType="pubmed">28090318</ArticleId></ArticleIdList></Reference><Reference><Citation>Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">27417494</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front. Immunol. 2012;3:334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3492872</ArticleId><ArticleId IdType="pubmed">23162552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes HR, Crill WD, Chang GJ. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J. 2012;9:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3424142</ArticleId><ArticleId IdType="pubmed">22709350</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM. et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell. 2017;168(6):1114&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388441</ArticleId><ArticleId IdType="pubmed">28222903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Welsh JP, Chan W, Swartz JR. Escherichia coli-based cell free production of flagellin and ordered flagellin display on virus-like particles. Biotechnol Bioeng. 2013;110(8):2073&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">23519642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CH, Tang N, Jan JT, Huang MH, Lu CY, Chiang BL. et al. Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection. Vaccine. 2015;33(35):4321&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25858857</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K, Maki-Yonekura S, Namba K. Complete atomic model of the bac-terial flagellar filament by electron cryomicroscopy. Nature. 2003;424(6949):643&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904785</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol. 1999;73(1):783&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC103889</ArticleId><ArticleId IdType="pubmed">9847388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs J, Chu H, O'Day P, Pyles R, Bourne N, Das SC. et al. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. Vaccine. 2014;32(48):6537&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252871</ArticleId><ArticleId IdType="pubmed">25239488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Bhamarapravati N, Gubler DJ. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology. 1997;230:300&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143286</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N. et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol. 2000;74:3020&#x2013;3028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111800</ArticleId><ArticleId IdType="pubmed">10708416</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccines for protection against dengue fever. Vaccine. 2011;29:7251&#x2013;7260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4592106</ArticleId><ArticleId IdType="pubmed">21777638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410(6832):1099&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11323673</ArticleId></ArticleIdList></Reference><Reference><Citation>Honko AN, Mizel SB. Effects of flagellin on innate and adaptive immunity. Immunol Res. 2005;33(1):83&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">16120974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol. 2010;185(10):5677&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756556</ArticleId><ArticleId IdType="pubmed">21048152</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajam IA, Dar PA, Shahnawaz I, Jaume JC, Lee JH. Bacterial flagellin-a potent immunomodulatory agent. Exp Mol Med. 2017;49(9):e373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5628280</ArticleId><ArticleId IdType="pubmed">28860663</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P. et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis. 2007;195:1607&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pubmed">17471430</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Song L, Beasley DW, Putnak R, Parent J, Misczak J. et al. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys. Clin Vaccine Immunol. 2015;22(5):516&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412944</ArticleId><ArticleId IdType="pubmed">25761459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawiecki AB, Christofferson RC. Zika virus-induced Antibody Response Enhances Dengue Virus Serotype 2 Replication In Vitro. J Infect Dis. 2016;214(9):1357&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pubmed">27521359</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA. et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356(6334):175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5714274</ArticleId><ArticleId IdType="pubmed">28360135</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS. et al. Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. Emerg Infect Dis. 2017;23(5):773&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5403059</ArticleId><ArticleId IdType="pubmed">28418292</ArticleId></ArticleIdList></Reference><Reference><Citation>Keasey SL, Pugh CL, Jensen SM, Smith JL, Hontz RD, Durbin AP. et al. Antibody Responses to Zika Virus Infections in Environments of Flavivirus Endemicity. Clin. Vaccine Immunol. 2017;24(4):pii. e00036-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382833</ArticleId><ArticleId IdType="pubmed">28228395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman MG, Quicke KM, O'Neal JT, Arora N, Machiah D, Priyamvada L. et al. Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages. Cell Host Microbe. 2018;24(5):731&#x2013;742. e736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394860</ArticleId><ArticleId IdType="pubmed">30439342</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler AM, Tang WW, Young MP, Mamidi A, Viramontes KM, McCauley MD. et al. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice. Cell Host Microbe. 2018;24(5):743&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250068</ArticleId><ArticleId IdType="pubmed">30439343</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JA, Singh G, Acklin JA, Lee S, Duehr JE, Chokola AN. et al. Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy. Immunity. 2019;50:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6947917</ArticleId><ArticleId IdType="pubmed">30737148</ArticleId></ArticleIdList></Reference><Reference><Citation>George J, Valiant WG, Mattapallil MJ, Walker M, Huang YS, Vanlandingham DL. et al. Prior exposure to Zika virus significantly enhances peak dengue-2 viremia in rhesus macaques. Sci. Rep. 2017;7(1):10498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585353</ArticleId><ArticleId IdType="pubmed">28874759</ArticleId></ArticleIdList></Reference><Reference><Citation>Terzian ACB, Schanoski AS, Mota MTO, da Silva RA, Estofolete CF, Colombo TE. et al. Viral load and cytokine response profile does not support antibody-dependent enhancement in dengue-primed Zika virus-infected patients. Clin. Infect. Dis. 2017;65(8):1260&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849103</ArticleId><ArticleId IdType="pubmed">29017246</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858873</ArticleId><ArticleId IdType="pubmed">29097492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, Baker TS. et al. Conformational changes of the flavivirus E glycoprotein. Structure. 2004;12(9):1607&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152830</ArticleId><ArticleId IdType="pubmed">15341726</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16(2):170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445969</ArticleId><ArticleId IdType="pubmed">25501631</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015;520(7545):109&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">25581790</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Song J, Lu X, Deng YQ, Musyoki AM, Cheng H. et al. Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. Cell Host Microbe. 2016;19(5):696&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">27158114</ArticleId></ArticleIdList></Reference><Reference><Citation>Long F, Doyle M, Fernandez E, Miller AS, Klose T, Sevvana M. et al. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. Proc Natl Acad Sci U S A. 2019;116(5):1591&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358714</ArticleId><ArticleId IdType="pubmed">30642974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392(1):103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8(3):271&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapparapu G, Fernandez E, Kose N, Bin C, Fox JM, Bombardi RG. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540(7633):443&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583716</ArticleId><ArticleId IdType="pubmed">27819683</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>